Caroline Helwick | Authors

ST Michaels HOSPITAL

900 Illinois Ave.

Stevens Point

54481

Articles

FDA simplifies patient access to investigational drugs

May 13, 2010

Rules balance access to promising new therapies against the need to protect patient safety.

High dietary polyamines may foster colorectal adenomas

April 15, 2010

A high intake of dietary polyamines, which are commonly found in orange juice, corn, red meat, peas, and nuts, has been linked to the size and grade of colorectal adenomas found on screening colonoscopy.

Colon Cancer: Microsatellite instability stymies doctors

April 14, 2010

Confusion over important prognostic indicator may lead to unnecessary treatment.

IGF-Receptor Inhibitor and Sunitinib Show Activity in Stage IV Pancreatic Cancer

March 18, 2010

A novel IGF-receptor inhibitor stabilized disease in a majority of pancreatic cancer patients, according to a report at the 2010 GI Cancers Symposium.

Effective Rx for KRAS-mutated colon cancer

March 17, 2010

A primer on managing the chemorefractory patient from Eric Van Cutsem, MD, PhD.

The Optimal Rx for Pancreatic Cancer: Stop It Before It Starts

March 17, 2010

Screening is the key to protecting those at risk for pancreatic cancer, according to presenters at the 2010 Gastrointestinal Cancers Symposium.

Second-line bevacizumab plus chemo improves PFS

February 23, 2010

The RIBBON-2 trial met its primary endpoint of prolonged progression-free survival.

Single-agent gefitinib doubles time-to-progression in non-small-cell lung cancer patients with EGF.

February 22, 2010

The seminal IPASS study by Tony Mok, MD, and colleagues demonstrated moderate efficacy for gefitinib (Iressa) in advanced non–small–cell lung cancer patients, most notably in patients with predictive factors, including adenocarcinoma histology, no history of smoking, and Asian ethnicity.

High-dose fulvestrant improves outlook in advanced ca

February 22, 2010

Higher doses of the estrogen-receptor antagonist fulvestrant (Faslodex) may increase treatment benefit without increasing toxicity, according to results from the international, randomized, double-blind phase III CONFIRM trial.

Denosumab protects bones better than zoledronic acid in metastatic disease

February 18, 2010

The RANK ligand inhibitor was better tolerated and more convenient for patients with skeletal metastasis.